Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00PXQ
|
|||
| Former ID |
DPR000043
|
|||
| Drug Name |
Fananserin
|
|||
| Synonyms |
127625-29-0; RP 62203; Fananserin [USAN:INN]; RP-62203; UNII-38QJ762ET6; CHEMBL83894; C23H24FN3O2S; VGIGHGMPMUCLIQ-UHFFFAOYSA-N; 38QJ762ET6; NCGC00167808-01; DSSTox_RID_81871; DSSTox_CID_26743; 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; 2H-Naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide; DSSTox_GSID_46743; [3H]fananserin; CAS-127625-29-0; Fananserin (USAN/INN); [3H]RP62203; [3H]RP-62203; AC1L1TX5; RP 62203; 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Terminated | [1], [2] | |
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24FN3O2S
|
|||
| Canonical SMILES |
C1CN(CCN1CCCN2C3=CC=CC4=C3C(=CC=C4)S2(=O)=O)C5=CC=C(C=C5)F
|
|||
| InChI |
1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2
|
|||
| InChIKey |
VGIGHGMPMUCLIQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 127625-29-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8187052, 14856245, 43118132, 47205811, 50064308, 50112947, 57314111, 78566174, 85212007, 85788217, 103922972, 104321638, 129471014, 134339513, 135018988, 135698206, 137237442, 140010545, 140173976, 144206140, 160703995, 162023484, 163124146, 170466120, 178100286, 178102086, 179149761, 198976575, 204372620, 224932293, 226676066, 241376050, 249617645, 250071166, 252156679
|
|||
| ChEBI ID |
CHEBI:92159
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5434). | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 3 | Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. Pharmacological characterization of [3H]RP 62203 binding in the rat brain. Eur J Pharmacol. 1993 Mar 16;233(1):37-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.